GIST data sign a setback for Tasigna against Glivec as giant Novartis axes trial
This article was originally published in Scrip
Executive Summary
Novartis has discontinued a Phase III trial investigating its second generation BCR-ABL inhibitor, Tasigna (nilotinib), as a first-line treatment for gastrointestinal stromal tumours (GIST). The decision was based on the recommendation of an independent data monitoring committee and came after interim efficacy results suggested that the product is unlikely to show superiority over Glivec (Novartis' imatinib; Gleevec).